title: Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice.
abstract: The increasing prevalence of obesity worldwide is associated with a parallel increase in non-alcoholic fatty liver disease (NAFLD). To investigate the effect of Lactobacillus johnsonii BS15 on NAFLD, 120 male ICR mice were randomly divided into four groups and administrated with BS15 (2 × 10(7) cfu/0.2 mL or 2 × 10(8) cfu/0.2 mL) or phosphate buffered saline (PBS) throughout a 17-week experimental period. The mice were fed with normal chow diet (NCD) 5 weeks before the experimental period. Afterward, with the exception of the PBS group, NCD was changed into high-fat diet (HFD) for the remaining experimental period. Results showed that BS15-treated HFD mice were protected from hepatic steatosis and hepatocyte apoptosis. BS15 exhibited a positive effect on liver lipid peroxidation through an anti-oxidative stress activity by enhancing the liver antioxidant defense system. In addition, BS15 inhibited the insulin resistance; decreased the mRNA levels of acetyl-CoA carboxylase 1, fatty acid synthase, and peroxisome proliferator-activated receptor γ; and increased the expression of the fasting-induced adipose factor in livers. Meanwhile, BS15 attenuated mitochondria abnormalities when the content of uncoupling protein-2 decreased and cytochrome c increased in NAFLD mice. BS15 also reduced the level of serum lipopolysaccharide in NAFLD mice by lowering the intestinal permeability and adjusting gut flora, followed by the downregulation of the TNFα mRNA level in liver and the serum level of C-reactive protein. These findings suggest that BS15 may be effective in preventing NAFLD induced by HFD.
authors.affiliation: Animal Microecology Institute, College of Veterinary Medicine, Sichuan Agricultural University, Ya'an, 625014, China.
authors.forename: Jinge
authors.initials: J
authors.lastname: Xin
authors.forename: Dong
authors.initials: D
authors.lastname: Zeng
authors.forename: Hesong
authors.initials: H
authors.lastname: Wang
authors.forename: Xueqin
authors.initials: X
authors.lastname: Ni
authors.forename: Dan
authors.initials: D
authors.lastname: Yi
authors.forename: Kangcheng
authors.initials: K
authors.lastname: Pan
authors.forename: Bo
authors.initials: B
authors.lastname: Jing
mesh_terms: D000103:Acetyl-CoA Carboxylase / Q000235:genetics / Q000276:immunology; D000818:Animals; D017209:Apoptosis; D064429:Fatty Acid Synthases / Q000235:genetics / Q000276:immunology; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007333:Insulin Resistance; D007778:Lactobacillus / Q000502:physiology*; D008099:Liver / Q000166:cytology / Q000201:enzymology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008820:Mice, Obese; D008928:Mitochondria / Q000276:immunology*; D065626:Non-alcoholic Fatty Liver Disease / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology / Q000517:prevention & control*; D019936:Probiotics / Q000008:administration & dosage*
chemical_list: D064429:Fatty Acid Synthases; D000103:Acetyl-CoA Carboxylase